ENTA - Enanta Pharma shows positive effect in early-stage study for hep B therapy

Updating the results from the first two dose cohorts of Part 2 of its Phase 1b study, Enanta Pharmaceuticals ([[ENTA]] -2.1%) said that its experimental therapy, EDP-514 yielded positive data in a certain segment of chronic hepatitis B virus ((HBV)) patients.The pharmacokinetics observed in the study were supportive of once-daily dosing, the company said.HBV patients who were already receiving a nucleoside reverse transcriptase inhibitor ((NUC)) were randomized to receive 200 mg (n=6), 400 mg (n=6), 800 mg (n=6) of EDP-514 or placebo (n=6) daily in the double-blind trial for 28 days.In the first two cohorts, there were no liver enzyme elevations or other laboratory abnormalities, the company said. The grade 3 or serious adverse events (AEs) were not witnessed during the treatment period and the 4-week follow-up.The mean decline of HBV RNA of 1 log was seen in patients dosed with EDP-514 compared to 0.3 log in the placebo arm after 28

For further details see:

Enanta Pharma shows positive effect in early-stage study for hep B therapy